Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
-3.47% $0.885
America/New_York / 9 mai 2022 @ 00:00
FUNDAMENTALS | |
---|---|
MarketCap: | 8.18 mill |
EPS: | -3.44 |
P/E: | -0.257 |
Earnings Date: | May 10, 2022 |
SharesOutstanding: | 9.25 mill |
Avg Daily Volume: | 6.37 mill |
RATING 2022-07-08 |
---|
B- |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Buy | |
Return On Equity: | Buy | |
Return On Asset: | Sell | |
DE: | Sell | |
P/E: | Strong Sell | |
Price To Book: | Strong Sell |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | n/a | n/a | ||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -0.257 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.04x |
Company: PE -0.257 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 0.754 - 1.016 ( +/- 14.81%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2022-04-15 | Desparbes Eric | Buy | 231 693 | Common Stock |
2022-04-15 | Neumann Clarke | Buy | 184 843 | Common Stock |
INSIDER POWER |
---|
100.00 |
Last 2 transactions |
Buy: 416 536 | Sell: 0 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $0.885 (-3.47% ) |
Volume | 2.78 mill |
Avg. Vol. | 6.37 mill |
% of Avg. Vol | 43.66 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Progenity, Inc., a biotechnology company, provides develops and commercializes molecular testing products in the United States. The company develops targeted oral delivery of biotherapeutics, including PGN-600, an orally delivered liquid formulation of tofacitinib for the treatment of ulcerative colitis; and PGN-001, an orally delivered variant of adalimumab for the treatment of ulcerative colitis. It also develops systemic oral delivery of biotherapeutics, which include PGN-OB, a combination product of a variant of adalimumab and the Oral Biotherapeutics Delivery System (OBDM) for the treatment of inflammatory conditions; and PGN-OB2, a combination product of a GLP-1 receptor agonist and the OBDS for the treatment of Type 2 diabetes. In addition, the company develops Recoverable Sampling System, an ingestible smart capsule designed to autonomously identify locations in the GI tract, collect, and preserve a sample for analysis; and PIL Dx, an ingestible smart capsule designed to sample, measure, and transmit results. It has partnership agreement with Ionis Pharmaceuticals to evaluate the OBDS for delivery of antisense oligonucleotides. The company was formerly known as Ascendant MDX, Inc. and changed its name to Progenity, Inc. in November 2013. The company was founded in 2010 and is headquartered in San Diego, California.